The Contribution of SELENOF to the Disproportionate Mortality Experienced by African American Men Due to Prostate Cancer
Abstract
Prostate cancer disproportionately affects African American men, and our laboratory has determined that an at-risk polymorphism in the gene for SELENOF is 10-times more frequent in the genomes of African Americans and this genetic variation is likely to result in lower SELENOF levels in tissues. Consistent with these observations is data indicating that the levels the SELENOF protein are lower in the prostate tumors of African American men as well. We have established that reduced levels of SELENOF are likely contributing to cancer progression. These data, along with observations on human tissues, provide solid evidence that the loss of SELENOF is mechanistically linked to prostate cancer aggressiveness and contribute to the disparity in disease outcome experienced by African Americans. Moreover, our recent data indicate the potential for a commercially available compound to enhance SELENOF levels, indicating that this approach can be developed into a new therapeutic strategy to impact prostate cancer mortality, especially among African American men.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1190643
Entities
People
- Alan M Diamond
Organizations
- University of Chicago